HB 519, legislation addressing the 340B drug discount program, passed the House and was introduced in the Senate. This bill would prohibit a pharmaceutical manufacturer from restricting, prohibiting or otherwise interfering with a 340B entity’s ability to acquire a 340B drug or participate in the 340B drug discount program.
Also in Utah, HB 257, legislation related to health insurance pharmacy benefits, passed the House and was introduced in the Senate. This bill would require a health benefit plan to ensure pharmaceutical rebates are used for certain purposes to benefit enrollees and require a PBM offers certain options to self-funded health benefit plans that (1) comply with provisions of Subsections 31A-22-643(4) and (5), collectively and individually; and (2) do not include spread pricing.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.